Effects of Galantamine on Cognition
|ClinicalTrials.gov Identifier: NCT01100775|
Recruitment Status : Active, not recruiting
First Posted : April 9, 2010
Last Update Posted : August 7, 2017
|Condition or disease||Intervention/treatment||Phase|
|Schizophrenia||Drug: Galantamine Drug: Galantamine or Placebo||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||24 participants|
|Intervention Model:||Crossover Assignment|
|Masking:||Double (Participant, Care Provider)|
|Official Title:||Effects of Galantamine on Cognition|
|Study Start Date :||May 2010|
|Estimated Primary Completion Date :||October 2018|
|Estimated Study Completion Date :||October 2018|
Active Comparator: 1
A lead-in 3 days of 4mg/ twice a day of galantamine (or placebo) followed by 8 mg (or placebo) on the 4th day, the day of testing.
Placebo Comparator: Placebo
Subjects will be randomly assigned to the two possible order of administration: the drug and then placebo, or the placebo and then drug.
Drug: Galantamine or Placebo
Subjects will be randomly assigned to the two possible order of administration: the drug and then placebo, or the placebo and then drug. Subjects will be given a lead-in 3 days of 4mg/ twice a day of galantamine (or placebo) followed by 8 mg (or placebo) on the 4th day, the day of testing.
- Determine effect of drug on cognition [ Time Frame: 2 hours ]The study will test whether the drug improves cognition (such as memory and attention) within few hours of taking the drug)
- Determine the effect of the drug on ability to express or experience emotions [ Time Frame: 2 hours ]We will test the effects of the drug on negative symptoms that include difficulty experiencing or expressing emotions, decreased social drive and decreased motivation.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01100775
|United States, Maryland|
|University of Maryland, Baltimore|
|Baltimore, Maryland, United States, 21228|
|Principal Investigator:||L. E. Hong, M.D.||University of Maryland|